New options in anticoagulation for the prevention of venous thromboembolism and stroke.
Year: 2011
Type: article
Abstract: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a national health problem that affects more than 200,000 Americans each year.1 VTE causes significant morbidity and mortality, surpassed only by coronary heart disease and stroke.2 Atrial fibrillation, the most common arrhythmia, is responsible for one-third of embolic stroke in the U.S.3 VTE and atrial fibrillation more commonly affect the elderly population; therefore, the incidence of both conditions can be expected to increase as the elderly population increases in number.
Warfarin (Coumadin, Bristol-Myers Squibb) has been the mainstay of therapy for the primary and secondary prevention of VTE and for the prevention of stroke secondary to atrial fibrillation. Despite warfarin’s proven efficacy, its use is complicated by the need for routine monitoring and numerous drug and dietary interactions. Fondaparinux (Arixtra, Glaxo-SmithKline) and enoxaparin (Lovenox, Sanofi-Aventis) are additional options used for VTE prevention; however, their use is limited by their parenteral formulation and cost. Additional agents for VTE and stroke prevention are necessary. An ideal anticoagulant agent would be orally administered and have few monitoring parameters, drug interactions, and adverse events. In this article, we review several oral anticoagulants that have recently been approved or are in advanced clinical development that meet these criteria.
Source: PubMed Central
Authors: Lisa R Clayville, Katherine Vogel Anderson, Shannon A Miller, Erin L St Onge
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2102785086
